Paraxanthine for Cognitive Function

Verdict: Weak, conflicted evidence; promising but unproven

Paraxanthine, a caffeine metabolite marketed as a "smoother" stimulant, shows small short-term gains in attention and working memory in a handful of tiny trials, but the evidence is weak and almost entirely funded by the ingredient's patent holder. It is not yet proven to meaningfully boost cognition, and major regulators and clinics have not endorsed it.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is held at weak (Tier C) because every human study comes from the same source. Four small double-blind RCTs (PMID 34836235, n=13; PMID 34960030, n=12; PMID 38725238, n=12; PMID PMC12777857, n=24) report statistically significant but modest acute improvements in vigilance, reaction time, and N-Back working memory at roughly 100-200 mg. All four, however, were industry-funded by the ENFINITY patent holder, with several authors named as inventors, and none has been independently replicated. There is no systematic review or meta-analysis.

The studies are also short (single-dose or up to 7 days) and underpowered, so they cannot confirm durable or real-world benefit. The widely promoted claim that paraxanthine is 'better than caffeine' rests on a single n=12 trial after a 10-km run (PMID 38725238); its headline cognitive gains were significant versus placebo (p=0.012-0.029), but the direct edge over caffeine reached only a non-significant trend (p=0.059).

Authorities have not endorsed it. The EU's EFSA still treats synthetic paraxanthine as an unauthorized novel food (application NF-2022-9030 under review), and Mayo Clinic, Cleveland Clinic, Harvard Health, and the Alzheimer's Association offer no supportive position, the latter noting no supplement has been proven to lastingly benefit cognition. The early signal is genuine but preliminary and conflicted.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.50
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
82%
Highly consistent evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.503
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Acute Paraxanthine Ingestion Improves Cognition and Short-Term Memory and Helps Sustain Attention in a DB PC Crossover Trial
PMID: 34836235 2021 RCT (double-blind) n = 13
Finding: Paraxanthine reduced BCST errors at hour 6 (p=0.04), improved 6-letter Sternberg absent reaction time at 2 h (p=0.03), and sustained PVT vigilance at 2 h (p=0.03) and 4 h (p=0.002)
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
Dose-Response of Paraxanthine on Cognitive Function: A Double Blind, Placebo Controlled, Crossover Trial
PMID: 34960030 2021 RCT (double-blind) n = 12
Finding: Acute and short-term benefits vs placebo at each dose; more consistent effects at 100 mg and 200 mg; no significant side effects (narrative; multiple per-dose p-values not pooled)
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
Paraxanthine provides greater improvement in cognitive function than caffeine after performing a 10-km run
PMID: 38725238 2024 RCT (double-blind) n = 12
Finding: PX increased correct BCST responses by 6.8% post-exercise (p=0.012), reduced PVT reaction times by 23.2% vs placebo (p=0.029), and reduced errors vs caffeine by 35.7% (p=0.059, trend); PX+CA showed no additive benefit
🟠 Limited quality ⚠️ Industry-funded
View on PubMed
Acute paraxanthine ingestion increases energy, focus, and satiety, enhancing postprandial cognitive performance in young adults
PMID: 2025 RCT (double-blind) n = 24
— See PubMed for details
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4b EU EFSA
Cautious
Paraxanthine is manufactured by chemical synthesis. As synthetic paraxanthine was not consumed to a significant degree in the EU before May 15, 1997, it is a novel food according to Regulation (EU) 2015/2283. The identity of synthetic paraxanthine (1,7-dimethyl-3H-purine-2,6-dione) has been analytically verified. source↗
L5e Specialty Society (condition-mapped)
Not addressed
Not a single food, beverage, ingredient, vitamin or supplement has been proven to prevent, treat or cure Alzheimer's or have a lasting effect on cognitive function or brain health. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-paraxanthine-001 繁體中文版 →